| Name | ns 1619 |
|---|---|
| Synonyms |
NS-1619, 10 mM in DMSO
1-[2-Hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2H-benzimidazol-2-one 1-(2-hydroxy-5-(trifluoroMethyl)phenyl)-5-(trifluoroMethyl)-1H-b 1-(2-Hydroxy-5-(Trifluoromethyl)Phenyl)-5-(Trifluoromethyl)-1H-Benzo[D]Imidazol-2-Ol NS1619;NS 1-[2-Hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl) 1-(2-Hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one NS 1619 (1,3-DIHYDRO-1-(2-HYDROXY-5-(TRI FLUOROMETHYL)PHEN 1,3-DIHYDRO-1-[2-HYDROXY-5-(TRIFLUOROMETHYL)PHENYL]-5-(TRIFLUOROMETHYL)-2H-BENZIMIDAZOL-2-ONE NS 1619, KCa1.1 channel activator Lopac-N-170 |
| Description | NS-1619 is a selective large conductance Ca2+-activated K+-channel activator.IC50 value: Target: Ca2+-activated K+-channel activatorNS 1619 (3-100 microM) produced a concentration-dependent inhibition of spontaneous activity in rat portal vein characterized by a reduction in the amplitude and duration of the tension waves. This inhibition was slightly potentiated in the presence of either charybdotoxin (250 nM) or penitrem A (1 microM) [1]. NS-1619 induced concentration-dependent activation of BKCa channels with a calculated EC50 of 32 microM. The NS 1619-induced activity was dependent on the presence of free Ca2+ at the intracellular surface, but was not associated with a change in channel voltage sensitivity [2]. NS 1619 (50 microM) inhibited the noradrenaline-induced contraction. NS 1619 (10-100 microM) reduced the high K+-induced contractions in a noncompetitive manner [3]. Inhalation of a 12 μM and 100 μM NS1619 solution significantly reduced RV pressure without affecting systemic arterial pressure. Blood gas analyses demonstrated significantly reduced carbon dioxide and improved oxygenation in NS1619-treated animals pointing towards a considerable pulmonary shunt-reducing effect. In PASMC's, NS1619 (100 μM) significantly attenuated PASMC proliferation by a pathway independent of AKT and ERK1/2 activation [4]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.563g/cm3 |
|---|---|
| Melting Point | 234 °C(dec.) |
| Molecular Formula | C15H8F6N2O2 |
| Molecular Weight | 362.22700 |
| Exact Mass | 362.04900 |
| PSA | 58.02000 |
| LogP | 4.06200 |
| Index of Refraction | 1.538 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |